France's Advanced Accelerator Applications raised almost $56.4 million in new financing to help advance new molecular imaging-related diagnostic tools and treatments in the U.S. and around the world.
Myriad Genetics is headed to Europe to help market a breast cancer test developed by Sividon Diagnostics, a Siemens Healthcare spinoff. With the move, Myriad is hoping to add some more diversity to its line of molecular diagnostics.
Myriad Genetics will sell a breast cancer test in Europe developed by a Siemens spinoff. The co-marketing deal reflects a continued effort by the Utah molecular diagnostic company to diversify, following a U.S. Supreme Court decision that enabled rivals to challenge the market dominance of one of its signature products.
Many new drugs these days are made with companion diagnostic tests in mind, and Amgen's treatment for metastatic colorectal cancer is no different. Illumina has inked a deal to develop a test that screens for patients who'd benefit most from the drug.
Illumina will develop a companion diagnostic test for Amgen's Vectibix, a drug designed to treat metastatic colorectal cancer that has U.S. and EU approval.
Dako has sealed a deal with yet another Big Pharma company to develop companion diagnostic tests for potential new cancer drugs. This time, it will work with Merck, a pharmaceutical giant facing some turmoil as it revamps its struggling R&D operations.
Roche is pairing a companion diagnostic test already linked to its Herceptin breast cancer drug with two new blockbuster treatments also produced by the company, bringing more of its personalized medicine development strategy to fruition.
Colorado startup Sundance Diagnostics said it will work with Germany's famed Max Planck Institute of Psychiatry to develop and commercialize a diagnostic blood test that would gauge suicide risk for patients taking antidepressants.
Researchers have been unable to determine why some depression patients respond better than others to the class of drugs that includes Prozac, Zoloft and Celexa. Now a team has uncovered a gene that may act as a biomarker for this type of patient, potentially helping to match the drug with the patient.
Despite some ongoing patent battles and mounting legal trouble, Myriad Genetics remains a heavy hitter in the world of cancer diagnostics, and now the Utah company has struck up a deal with drug developer BioMarin Pharmaceutical to use one of its molecular tests to develop a targeted cancer drug.